Study of AMV564 in Subjects With Advanced Solid Tumors
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Patrick Chun, MD
Amphivena Therapeutics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ucla
Los Angeles, California, United States
- Advent Health
Orlando, Florida, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- Northwestern University
Chicago, Illinois, United States
- Duke University Medical Center
Durham, North Carolina, United States
- the Christ Hospital
Cincinnati, Ohio, United States
- the Ohio State University
Columbus, Ohio, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- Next Oncology
San Antonio, Texas, United States
- University of Virginia
Charlottesville, Virginia, United States
- Peninsula Cancer Institute
Newport News, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 9 Oct 2019
- Primary completion
- 15 Dec 2021
- Completion
- 31 Dec 2021
- Last update posted
- 19 Oct 2021
- Registered enrollment
- 65
- Registry id
- NCT04128423
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.